This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Idenix Pharmaceuticals' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Stocks in this article: IDIX

The P&L, one of the things that we used to have on the top line was a royalty from Novartis related to our HBV compound, Tyzeka/Sebivo. In exchange for Novartis’ rights to compounds in our pipeline, we exchanged that royalty back to them as part of that transaction. And that was running at around a million a quarter, around $4 million a year. That’s pretty much it for the financials.

David Friedman - Morgan Stanley

And then you mentioned that you guys had previously been a sort of broader-focused antiviral company with an explicit focus in the last half a decade on HCV. Is there any intention to rebroaden? Or given that you guys have a number of HCV drugs in the clinic, is it your intention to focus exclusively on that part, carry that through? How are you thinking about that?

Ronald Renaud

It’s a great question. After Tyzeka/Sebivo, we clearly put our ambitions in HBV up on the shelf. And we were focused on HCV. And initially - I think some folks might remember - in HIV we had a non-nucleoside reverse transcriptase inhibitor called IDX899. That, preclinically, and even in the early proof of concept data, looked fantastic.

We ended up out-licensing that. HIV is obviously a big marketplace, and not one where we wanted to try to go alone with one compound. We out-licensed that to GSK, which became part of the ViiV Healthcare company, in a transaction that we did. I believe it was back in early 1999.

So after that, we used the financial resources gained from that transaction to really focus everything on HCV. And I think today we feel very strongly about making sure we get HCV right. We remain very, very confident in IDX184, IDX368. We have some additional nucleotide prodrugs that we’re going to bring forward, non G-based nucleotide prodrugs that will come forward during the span of the next 6 to 12 months.

3 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs